Author

Sarah Kinkel

The University of Melbourne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genomics· 2 Cancer Biology· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Andrew KeniryiD· 3 shared Kelsey A. BresliniD· 3 shared Marnie E. BlewittiD· 3 shared Quentin A. GouiliD· 3 shared Ellise A RoperiD· 2 shared Heather J LeeiD· 2 shared Iromi WanigasuriyaiD· 2 shared Matthew E. RitchieiD· 2 shared

Activity by Year

2020-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenomics

Andrew KeniryORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

Kendelle Joan Murphy, Cecilia R. Chambers, Daniel A. Reed, Lily M. Channon, Niamh EP Mills, Sophie E McKay, Victoria Lee, Anna E. Howell, Alice M. H. Tran, Max Nobis, Astrid Magenau, Janett Stoehr, Brooke Pereira, Nadia Kuepper, Shona Ritchie, , Paul Timpson

This paper shows that pulsed narmafotinib priming improves chemotherapy response in pancreatic cancer by reducing fibrosis and enhancing treatment efficacy.

bioRxiv · Jul 23, 2026 · PreprintCancer Biology

SMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome

Megan Iminitoff, Anna K. Le Fevre, Tamara Cameron, Hannah Kate Vanyai, Caleb Chew, Sarah Kinkel, Kelsey A. Breslin, Susanne Theiß, Quentin A. Gouil, Merlin C. Thomas, James M. Murphy, Christian Patrick Schaaf, Andrew Keniry, Marnie E. Blewitt

This study identifies SMCHD1 as a target for gene-activation therapy in Prader-Willi Syndrome by showing its role in repressing the PWS gene cluster and demonstrating gene activation in mouse models.

bioRxiv · May 14, 2026 · PreprintGenetics

Maternal SMCHD1 controls both imprinted Xist expression and imprinted X chromosome inactivation

Iromi Wanigasuriya, Sarah Kinkel, Tamara J Beck, Ellise A Roper, Kelsey A. Breslin, Heather J Lee, Andrew Keniry, Matthew E. Ritchie, Marnie E. Blewitt, Quentin A. Gouil

This study shows maternal SMCHD1 is essential for imprinted Xist expression and X chromosome inactivation in mouse embryos and placenta.

Epigenetics & Chromatin · Jul 17, 2022Peer-reviewedGenomics

Smchd1 is a maternal effect gene required for autosomal imprinting

Iromi Wanigasuriya, Quentin A. Gouil, Sarah Kinkel, Andrés Tapia del Fierro, Tamara J Beck, Ellise A Roper, Kelsey A. Breslin, Jessica M. Stringer, Karla J. Hutt, Heather J Lee, Andrew Keniry, Matthew E. Ritchie, Marnie E. Blewitt

This study identifies Smchd1 as a maternal effect gene that regulates imprinted expression of 16 genes by translating polycomb-mediated histone methylation marks into a heritable chromatin state.

eLife · Nov 13, 2020Peer-reviewedGenomics